NCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
16 trialsNCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01753297 2020-12-09
PRIORITI
Ipsen
Phase 4 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT01715129 2019-12-09
DKP 3M SC
Ipsen
Phase 3 Completed
NCT02005887 2019-05-29
TREND
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT01257425 2019-02-08
PAMIS
Ipsen
Phase 2 Completed
NCT01020448 2019-01-30
Triptocare
Ipsen
Phase 3 Completed
NCT00659373 2016-07-25
Co-SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01656161 2015-09-15
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT00751790 2014-07-25
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed